Catalent (CTLT)
(Delayed Data from NYSE)
$59.92 USD
-0.03 (-0.05%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $59.91 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.92 USD
-0.03 (-0.05%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $59.91 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum B VGM
Zacks News
Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report
by Zacks Equity Research
Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.
Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.
Catalent (CTLT) Q4 Earnings Miss Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -10% and 1.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q4 results are likely to be affected by soft segmental performances.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 22.64% and 216.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 2.56% and 88.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Catalent (CTLT) Up 3.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL
by Zacks Equity Research
Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.
Catalent (CTLT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View
by Zacks Equity Research
Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 30.77% and 11.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers
by Zacks Equity Research
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Catalent (CTLT) Expands Its Facility Capabilities in Shiga
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -22.22% and 28.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 0% and 23.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Stock Jumps 6.8%: Will It Continue to Soar?
by Zacks Equity Research
Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.